DN Initiatives, Centers, and Resources
Moving neuroscience research forward
NIA's Division of Neuroscience supports major initiatives, centers, and resources to advance Alzheimer's and related dementias and brain health research on many fronts.
The AMP-AD program is a precompetitive partnership among government, industry, and nonprofit organizations that focuses on discovering novel, clinically relevant therapeutic targets and on developing biomarkers to help validate existing therapeutic targets.
The ABC-DS study is a joint study conducted by two groups of research collaborators—Neurodegeneration in Aging Down Syndrome (NiAD) and Alzheimer's Disease in Down Syndrome (ADDS)—and is supported by NIA and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
The ACTC is expected to accelerate and expand studies for therapies in Alzheimer’s disease and related dementias. The infrastructure of 35 sites across the United States will address the timeframe, complexity and expense of the recruitment process and site activation for Alzheimer’s trials to find new and effective ways to treat or prevent these devastating disorders.
The Genetics of Alzheimer’s Disease Portfolio supports research to discover long term treatments for the disease by the identification of risk factor and protective genes and the underlying molecular pathways.
Launched in 2004, ADNI is an ongoing, longitudinal, multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease.
AlzPED is a publicly available, searchable, data resource that aims to increase the transparency, reproducibility and translatability of preclinical efficacy studies of candidate therapeutics for Alzheimer’s disease.
AD Translational Initiatives
CEHP is a trans-NIH initiative aiming to understand the positive and negative changes in cognition and emotion in adulthood, and what can be done to preserve and enhance positive outcomes.
DIAN is an international research effort to find solutions to treat or prevent this disease and, potentially, all forms of Alzheimer’s.
The MODEL-AD initiative works to develop, validate and disseminate new, precise animal models of Alzheimer’s disease.
M2OVE-AD is an NIH-led team-science venture to build a nuanced model of Alzheimer's disease that more accurately reflects its many causes and pathways.
Centers and Resources
NIA-funded Alzheimer's Disease Centers (ADCs) work to translate research advances into improved diagnosis and care, as well as find ways to treat and possibly prevent Alzheimer's disease and related dementias.
Funded by NIA, NACC has developed and maintains a large relational database of standardized clinical and neuropathological research data. NACC provides a valuable resource for both exploratory and explanatory Alzheimer's disease research. NACC data are freely available to all researchers.
Launched in 2010 as a joint collaboration between the NIA and the Alzheimer's Association, IADRP enables users to assess the portfolios of major organizations for areas of overlap as well as areas of opportunities in which to collaborate and coordinate in a collective effort to advance AD research.
The goal of the National Cell Repository for Alzheimer’s Disease (NCRAD) is to help researchers find genes that increase the risk for Alzheimer’s disease (AD) and dementia.
NIAGADS is the National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site. NIAGADS is a national genetics repository created by NIA to facilitate access by qualified investigators to genotypic data for the study of genetics of late-onset Alzheimer's disease.
The NIH Toolbox® is a comprehensive set of neuro-behavioral measurements that quickly assess cognitive, emotional, sensory, and motor functions.